Q-omics provides the consensus-scored LAPTM4A profile across patient tissues and cancer cell-line models. LAPTM4A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LAPTM4A is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LAPTM4A RNA expression shows 19,453 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where LAPTM4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAPTM4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAPTM4A survival associations across molecular data types. LAPTM4A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAPTM4A RNA expression–survival associations across cancer types. High LAPTM4A expression shows unfavorable associations in HNSC, UVM, LGG, LIHC and PAAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LAPTM4A RNA expression.
This table summarizes LAPTM4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LAPTM4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAPTM4A shows lower tumor expression in KICH, UCEC and LUAD and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher LAPTM4A RNA expression in tumor versus normal tissue (log2 FC = +0.962, t-test p < 0.001).
This table shows molecular features associated with LAPTM4A in patient tissues and cancer cell lines. In patient samples, LAPTM4A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAPTM4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
